Goldman Sachs Group Inc. Has $4.27 Million Stock Position in Ocular Therapeutix, Inc. $OCUL

Goldman Sachs Group Inc. cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 13.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 582,009 shares of the biopharmaceutical company’s stock after selling 90,613 shares during the quarter. Goldman Sachs Group Inc. owned 0.37% of Ocular Therapeutix worth $4,266,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Hsbc Holdings PLC increased its position in Ocular Therapeutix by 8.1% in the 1st quarter. Hsbc Holdings PLC now owns 19,573 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,472 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Ocular Therapeutix by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company’s stock valued at $755,000 after purchasing an additional 2,853 shares during the last quarter. Brooklyn Investment Group increased its holdings in shares of Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 3,155 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Ocular Therapeutix in the fourth quarter worth about $28,000. Finally, Wellington Management Group LLP boosted its position in shares of Ocular Therapeutix by 1.0% during the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company’s stock worth $3,991,000 after buying an additional 4,488 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Trading Down 2.3%

Shares of OCUL stock opened at $12.16 on Thursday. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $13.85. The firm has a fifty day moving average price of $12.16 and a 200-day moving average price of $9.35. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -9.50 and a beta of 1.50.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million during the quarter, compared to the consensus estimate of $13.12 million. During the same period in the prior year, the company posted ($0.26) EPS. The company’s quarterly revenue was down 17.7% on a year-over-year basis. As a group, equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Activity

In related news, insider Peter Kaiser sold 3,011 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $12.04, for a total value of $36,252.44. Following the sale, the insider directly owned 204,093 shares of the company’s stock, valued at $2,457,279.72. This represents a 1.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey S. Heier sold 3,063 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $12.04, for a total transaction of $36,878.52. Following the transaction, the insider directly owned 259,911 shares in the company, valued at approximately $3,129,328.44. This trade represents a 1.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,519 shares of company stock worth $367,865. 2.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

OCUL has been the subject of several recent analyst reports. Needham & Company LLC increased their price objective on Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Scotiabank decreased their price target on Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, August 6th. Chardan Capital assumed coverage on Ocular Therapeutix in a report on Monday. They set a “buy” rating and a $21.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday, May 29th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.83.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.